Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Silo Pharma (SILO) Debt to Equity (2020 - 2023)

Silo Pharma's Debt to Equity history spans 4 years, with the latest figure at $0.07 for Q1 2023.

  • For Q1 2023, Debt to Equity rose 816.9% year-over-year to $0.07; the TTM value through Mar 2023 reached $0.07, up 816.9%, while the annual FY2022 figure was $0.04, 23.63% down from the prior year.
  • Debt to Equity for Q1 2023 was $0.07 at Silo Pharma, up from $0.04 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.07 in Q1 2023 and bottomed at $0.0 in Q1 2021.
  • The 4-year median for Debt to Equity is $0.01 (2021), against an average of $0.02.
  • The largest annual shift saw Debt to Equity surged 1291.04% in 2021 before it plummeted 80.47% in 2022.
  • A 4-year view of Debt to Equity shows it stood at $0.0 in 2020, then soared by 1291.04% to $0.05 in 2021, then dropped by 23.63% to $0.04 in 2022, then soared by 98.51% to $0.07 in 2023.
  • Per Business Quant, the three most recent readings for SILO's Debt to Equity are $0.07 (Q1 2023), $0.04 (Q4 2022), and $0.0 (Q3 2022).